Sharp Therapeutics Corp.
SHRX.V
TSX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 09/30/2024 | ||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | |
| Total Other Revenue | -- | -- | -- | -- | |
| Total Revenue | -- | -- | -- | -- | |
| Cost of Revenue | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | |
| SG&A Expenses | 352.60K | 456.40K | 431.50K | 152.90K | |
| Depreciation & Amortization | -- | -- | -- | -- | |
| Other Operating Expenses | -- | -- | -- | -- | |
| Total Operating Expenses | 1.04M | 1.43M | 1.32M | 664.60K | |
| Operating Income | -1.04M | -1.43M | -1.32M | -664.60K | |
| Income Before Tax | -1.09M | 559.10K | -3.25M | -679.60K | |
| Income Tax Expenses | -- | -- | -- | -- | |
| Earnings from Continuing Operations | -1.09M | 559.10K | -3.25M | -679.60K | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -- | -- | -- | -- | |
| Net Income | -1.09M | 559.10K | -3.25M | -679.60K | |
| EBIT | -1.04M | -1.43M | -1.32M | -664.60K | |
| EBITDA | -1.03M | -1.43M | -1.32M | -660.20K | |
| EPS Basic | -0.04 | 0.02 | -0.12 | -12.96 | |
| Normalized Basic EPS | -0.02 | 0.01 | -0.07 | -- | |
| EPS Diluted | -0.04 | 0.02 | -0.12 | -12.96 | |
| Normalized Diluted EPS | -0.02 | 0.01 | -0.07 | -- | |
| Average Basic Shares Outstanding | 29.98M | 29.67M | 28.22M | -- | |
| Average Diluted Shares Outstanding | 29.98M | 29.67M | 28.22M | 139.30K | |
| Dividend Per Share | -- | -- | -- | -- | |
| Payout Ratio | -- | -- | -- | -- | |